Moreover, in vivo analyses demonstrated that these changes were immunologically relevant, as CN133 alone treatment resulted in remarkably decreased PMN-MDSC population and functional molecules secretion of PMN-MDSCs in the TME and blood, and improved CD8 + T cells mediated lysis to prostate cancer cells by secretion of granzyme B and perforin. The gene discussed is CD8A; the disease is prostate cancer.